Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin-1 carrying Tn antigen (Tn-MUC1) is a tumor-associated glycoform of Mucin-1 (MUC1), a transmembrane glycoprotein normally expressed on the apical surface of simple glandular epithelial cells. During malignant transformation, cells undergo loss of apical-basal polarity and experience dysregulation of the O-glycosylation machinery, such as the inactivation of the molecular chaperone Cosmc (C1GALT1C1). This leads to the expression of aberrantly glycosylated, hypoglycosylated MUC1 carrying truncated O-glycans, most notably the Tn antigen (GalNAc-alpha-1-O-Ser/Thr). Unlike normal MUC1, which is heavily glycosylated and shielded from immune recognition, Tn-MUC1 exposes unique, highly cancer-specific neoepitopes that are virtually absent in healthy tissues, making it an exceptionally attractive target for selective cancer immunotherapy.
Tn-MUC1 is overexpressed in a wide range of epithelial cancers (adenocarcinomas), including breast, pancreatic, ovarian, non-small cell lung, and prostate cancers, as well as hematological malignancies like multiple myeloma and leukemia. Therapeutic strategies targeting Tn-MUC1 include chimeric antigen receptor (CAR) T-cell therapies (such as CART-TnMUC1-01), monoclonal antibodies (such as gatipotuzumab/PankoMab-GEX), antibody-drug conjugates (ADCs), and dendritic cell vaccines loaded with Tn-MUC1 glycopeptides. These agents exploit the tumor-specificity of the Tn-MUC1 glycoform to induce targeted tumor cell lysis via direct cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), or T-cell-mediated immune responses, while sparing normal tissues.
Chimeric antigen receptor T-cell (CAR-T) therapy targeting Tn-MUC1; Antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated by monoclonal antibodies; Antibody-drug conjugate (ADC) mediated cytotoxicity; Active immunotherapy via dendritic cell vaccination loaded with Tn-MUC1 glycopeptide
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin-1 carrying Tn antigen (Tn-MUC1).